PI3-kinase-dependent propofol treatment abolishes Mcl-1 down-regulation in primary neutrophils and ATRA-differentiated granulocytic HL60 cells.

<p>(A) Isolated human primary neutrophils and (B) ATRA (1 μM)-differentiated granulocytic HL60 cells were treated with propofol with or without LY294002 treatment for the indicated time points. Western blot analysis showing the expression of Mcl-1; β-actin was used as the loading control. One representative dataset obtained from three individual experiments is shown. The changes in the ratio of Mcl-1 and β-actin are also shown. The data are shown as the means ± SD of three individual experiments. *<i>P <</i> 0.05 compared with untreated at 0 h. #<i>P <</i> 0.05 compared with untreated at 24 h or day 6. †<i>P <</i> 0.05 compared with propofol. ns, not significant compared with untreated at 24 h or day 6.